Cantor Fitzgerald initiated coverage on Silence Therapeutics
Stocks in this Quantisnow insightHealth Care
Historical context for SLN
Across the 9 sessions after earlier SLN headlines, the stock closed higher 6 times and lower 3 times, with a median move of 4.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | SLN | SPY |
|---|---|---|---|
| Jun 11, 2026 | Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera | +11.3% | +1.7% |
| May 27, 2026 | Silence Therapeutics to Participate in Jefferies Global Healthcare Conference | +2.4% | -0.0% |
| May 12, 2026 | Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference | -5.3% | -0.2% |
| May 7, 2026 | Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results | -5.6% | -0.3% |
| Mar 5, 2026 | Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results | -4.8% | -0.6% |
| Dec 15, 2025 | Silence Therapeutics Announces Leadership Changes | +4.4% | -0.2% |
Quantisnow market dataNASDAQ
SLN
Silence Therapeutics Plc
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for SLN
Full SLN profile on Quantisnow Follow SLN and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time